ArticleFrontiers in oncology2026
Trends, survival and regional control of sentinel lymph node biopsy versus axillary dissection in cN0 breast cancer: a multicenter cohort in China.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trials show that sentinel lymph node biopsy (SLNB) can replace completion axillary lymph node dissection (ALND) for selected cN0 patients without compromising survival but real-world evidence from non-Western settings especially on regional nodal control remains limited. Methods: We identified 53,758 female patients with cN0, pT1-3, pN0-1 breast cancer from the National Cancer Center Oncology Information Database (2013-2022). For pN1, survival analyses were restricted to 2017-2022. Propensity score matching and competing-risks models were employed to compare overall survival, breast cancer specific survival, and regional nodal recurrence (RNR) between SLNB and ALND. Results: SLNB use increased from 18.8% to 75.3% in pN0 and from 9.7% to 48.2% in pN1. In pN0, 5-year RNR was similar for SLNB versus ALND (1.06% vs 0.96%; adjusted SHR 1.03). In pN1, SLNB was associated with higher 5-year RNR after breast-conserving surgery (BCS) (4.99% vs 1.27%; adjusted SHR 4.44; P = 0.033), most pronounced for Ki-67 ≥30% (SHR 12.79; P = 0.012) and no special type histology (SHR 5.90; P = 0.017). In the mastectomy cohort, 5-year RNR did not differ between SLNB and ALND (3.01% vs 2.05%; P = 0.946; adjusted SHR 1.22), except among patients without endocrine therapy (SHR 6.28; P = 0.01). Conclusion: Axillary de-escalation has been widely adopted in China and appears oncologically safe for patients with pN0 disease and for those with pN1 disease undergoing mastectomy. In contrast, among patients with pN1 disease treated with breast-conserving surgery, SLNB was associated with a higher risk of regional nodal recurrence. When ALND is omitted, guideline-concordant adjuvant management may be important to maintain regional control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.